A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer

Journal of Urology

Volumn 156, Issue 6, 1996, Pages 1934-1941

  Pawinski, A ^a   Sylvester, R ^a   Kurth, K H ^a   Bouffioux, C ^a   Van Der Meijden, A ^a   Parmar, M K B ^a   Bijnens, L ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

bladder neoplasms; drug therapy

Indexed keywords

ADJUVANT CHEMOTHERAPY; ARTICLE; BLADDER CANCER; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR RECURRENCE;

EID: 0030002747     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65396-5     Document Type: Article

References (32)

1. Jensen O.M. Esteve J. Moller H. Renard H. Cancer in the European community and its member states. Eur. J. Cancer 26 1990 1167
2. American Cancer Society Cancer Facts & Figures--1995 1995 American Cancer Society Atlanta, Georgia
3. Green D.F. Robinson M.R.G. Glashan R. Newling D. Dalesio O. Smith P.H. Does intravesical chemotherapy prevent invasive bladder cancer? J. Urol. 131 1984 33
4. Kurth, K. H., Denis, L., Ten Kate, F. F. J. W., Sylvester, R., De Pauw, M., Bouffioux, C., Debruyne, F. M. J., Pavone-Macaluso, M. and Oosterlinck, W.: Prognostic factors in superficial bladder tumors. In: Transitional Cell Malignancy. Edited by M. S. Soloway. Philadelphia, pp. 471-483, 1992.
5. Herr H.W. Laudone V.P. Whitmore W.F. Jr. An overview of intravesical therapy for superficial bladder tumors. J. Urol. 138 1987 1363
6. Schulman C. Robinson M. Denis L. Smith P. Viggiano G. de Pauw M. Dalesio O. Sylvester R. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. Eur. Urol. 8 1982 207
7. Oosterlinck W. Kurth K.H. Schroder F. Bultinck J. Hammond B. Sylvester R. members of European Organization for Research and Treatment of Cancer Genitourinary Group A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta,T1 papillary carcinoma of the bladder J. Urol. 149 1993 749
8. Kurth K.H. Schroder F.H. Tunn A. Ay R. Pavone-Macaluso M. Debruyne F. de Pauw M. Dalesio O. ten Kate F. members of European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of an European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone J. Urol. 132 1984 258
9. Newling D.W. Robinson M.R. Smith P.H. Byar D. Lockwood R. Stevens I. de Pauw M. Sylvester R. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective randomised phase III study performed by the EORTC GU Group. EORTC Genitourinary Tract Cancer Cooperative Group Eur. Urol. 27 1995 110
10. MRC Working Party on Urological Cancer The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC study. Brit J. Urol. 57 1985 680
11. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomised trial. Brit J. Urol. 73 1994 632
12. Tolley D.A. Hargreave T.B. Smith P.A. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Brit. Med. J. 296 1988 1759
13. Bouffioux Ch. Denis L. Oosterlinck W. Viggiano G. Vergison B. Keuppens F. de Pauw M. Sylvester R. Cheuvart B. members of European Organization for Research and Treatment of Cancer Genitourinary Group Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of European Organization for Research and Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin J. Urol. 148 1992 297
14. Bouffioux Ch. Kurth K.H. Bono A. Oosterlinck W. Kruger C.B. de Pauw M. Sylvester R. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group J. Urol. 153 1995 934 part 2
15. Debruyne F.M. van der Meijden A.P. Goebers A.D. Franssen M.P. van Leeuwen M.J.W. Steerenberg P.A. de Jong W.H. Ruitenberg J.J. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial Urology suppl. 3 1988 20
16. Gelber R.D. Goldhirsch A. Meta-analysis: the fashion of summing-up evidence. Part I: rationale and conduct Ann. Oncol. 2 1991 461
17. International Union Against Cancer TNM Classification of Malignant Tumours 3rd ed. 1978 Imprimerie G. de Buren Geneva
18. Yusuf S. Peto R. Lewis J. Collins R. Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog. Cardiovasc. Dis. 27 1985 335
19. Early Breast Cancer Trialists' Collaborative Group Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. New Engl. J. Med. 319 1988 1681
20. Kaplan E.L. Meier P. Non-parametric estimation from incomplete observations. J. Amer. Stat. Ass. 53 1958 457
21. Early Breast Cancer Trialists' Collaborative Group Treatment of Early Breast Cancer: Worldwide Evidence 1985-1990 vol. 1 1990 Oxford University Press Oxford
22. Sonneveld P. Kurth K.H. Hagemeyer A. Abels J. Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma. Cancer 65 1990 23
23. Friedman D. Moopan U.M.M. Rosen Y. Kim H. The effect of intravesical instillations of thiotepa, mitomycin C, and Adriamycin on normal urothelium: an experimental study in rats. J. Urol. 145 1991 1060
24. Soloway M.S. Murphy W.M. de Furia M.D. Crooke S. Finebaum P. The effect of mitomycin C on superficial bladder cancer. J. Urol. 125 1981 646
25. Lamm D.L. Blumstein B.A. Crawford E.D. Montie J.E. Scardino P. Grossman H.B. Stanisic T.H. Smith J.A. Jr. Sullivan J. Sarosdy M.F. Crissman J.D. Coltman C.A. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. New Engl. J. Med. 325 1991 1205
26. Herr H.W. Schwalb D.M. Zhang Z.F. Sogani P.C. Fair W.R. Whitmore W.F. Jr. Oettgen H.F. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a perspective randomized trial. J. Clin. Oncol. 13 1995 1404
27. Lamm D.L. Griffith G. Intravesical therapy: does it affect the natural history of superficial bladder cancer? Sem. Urol. 10 1992 39
28. Pagano F. Bassi P. Milani C. Meneghini A. Maruzzi D. Garbeglio A. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol. 146 1991 32
29. Martinez-Pineiro J.A. Leon J.J. Martinez-Pineiro L. Jr. Fiter L. Mosteiro J.A. Navarro J. Garcia Matres M. Carcamo P. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol. 143 1990 502
30. Rintala E. Jauhiainen K. Alfthan O. The Finnbladder Research Group MMC and BCG in Intravesical Chemotherapy and Immunotherapy of Superficial Bladder Cancer. EORTC GU Group Monograph 6. 1989 Alan R. Liss, Inc. New York 271 274
31. Soloway M.S. Perry A. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C. J. Urol. 137 1987 871
32. Lamm D.L. Blumenstein B.A. Crawford E.D. Crissman J.D. Lowe B.A. Smith J.A. Jr. Sarosdy M.F. Schellhamer P.F. Sagalowsky A.I. Messing E.M. Loehrer P. Grossman H.B. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol. Oncol. 1 1995 119